story of the week
First-Line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-Line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial
Lancet 2021 Jan 21;[EPub Ahead of Print], P Baas, A Scherpereel, AK Nowak, N Fujimoto, S Peters, AS Tsao, AS Mansfield, S Popat, T Jahan, S Antonia, Y Oulkhouir, Y Bautista, R Cornelissen, L Greillier, F Grossi, D Kowalski, J Rodríguez-Cid, P Aanur, A Oukessou, C Baudelet, G ZalcmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.